Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
25 hedge funds and large institutions have $5.47M invested in Agile Therapeutics in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
3% more capital invested
Capital invested by funds: $5.32M → $5.47M (+$148K)
14% less funds holding
Funds holding: 29 → 25 (-4)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$549K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$175K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$33.7K |
| 4 |
BlackRock
New York
|
+$13.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$302K |
| 2 |
NIM
Needham Investment Management
New York
|
-$115K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$65.9K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$34K |
| 5 |
VF
Virtu Financial
New York
|
-$24.5K |
AGRX Hedge Fund Activity: Q4 2018 in Review
25 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2018, worth a combined $5.47M — up 2.8% from $5.32M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of AGRX and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $549K. The largest seller was Vanguard Group, cutting an estimated $302K.
- 25 institutional investors held Agile Therapeutics (AGRX) as of Q4 2018, down from 29 in Q3 2018.
- Funds reported $5.47M of Agile Therapeutics stock for Q4 2018, up 2.8% quarter-over-quarter.
- 3 funds opened new Agile Therapeutics positions in Q4 2018 and 6 closed out, a net change of -3 holders.
- The largest Agile Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $549K added.
- The largest Agile Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $302K sold.
Based on aggregated 13F filings for Q4 2018.